SOLICITATION NOTICE
B -- Defining Host Gene Expression Profiles in Cancers in SUCCEED Study
- Notice Date
- 8/27/2009
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-90211-MM
- Archive Date
- 9/26/2009
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections & Immunoepidemiology Branch (IIB) plans to procure on a sole source basis for a study to conduct parallel evaluation on epithelial cells and stromal cells with Dr. Paul Ahlquist, Institute of Molecular Virology, University of Wisconsin, 1525 Linden Dr., Madison< WI 53706. The contractor shall define host gene expression profiles in cancer and CIN3 by cervic cell type and disease status in the Study to Understand Cervical Cancer Early Endpoints Determinants (SUCCEED). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 621511 and the business size standard is $13.5M. Period of performance shall be from September 19, 2009 or date of award, whichever is later, for twelve months. This will be awarded as a Firm Fixed Price type contract. The main objective of SUCCEED is to identify host and viral biomarkers that will distinguish those women with HPV infections that are likely to clear infection from those that are likely to have persistent infection and progress to cervical cancer. As part of the SUCCEED study, frozen specimens from cervix lesions representative of the disease continuum (normal, CIN1, CIN2, CIN3, cancer) have been embedded in cryomolds and flash frozen in liquid nitrogen. This protocol for frozen cervix tissue procurement was implemented for preservation of RNA which is intended to be extracted from pure cell populations and processed to define host and viral gene expression profiles. The specific objective of this procurement is to expand previous studies and evaluate SUCCEED tissue specimens to include all cancers and precancers collected to date. We wish to evaluate host gene expression, microRNA expression, and extract DNA for HPV analysis including genotyping from microdissected stromal cells and epithelial cells. From both epithelial and stromal cells, we seek to extract RNA and DNA. RNA will be used to evaluate host gene expression and will be evaluated with the Affymetrix U133 Plus 2.0 human genome microarray, and to evaluate microRNA expression array. This effort is to be conducted on all cancers and precancers with normal or low-grade HPV-infected tissues as comparison from the SUCCEED study to date, and will answer critical scientific questions for which SUCCEED was designed to address. The present contract aims to conduct parallel evaluation of epithelial cells and stromal cells using mRNA and microRNA analyses. In previous contracts, this laboratory has optimized laser capture microdissection in cervical tissue, RNA extraction and amplification, and conduct of the Affymetrix U133 Plus 2.0 human expression array chip. Previous SUCCEED tissue specimens were evaluated in the laboratory of Dr. Paul Ahlquist. Because results from the selected samples will be combined with the data from the previous contracts, it is imperative for study validity that the evaluation of SUCCEED samples be conducted within the same laboratory using the same optimized protocols and assays as previously conducted. This would ensure direct and valid comparability of gene expression profiles. Market research determined that the same laboratory methods and supplies were critical as different data points are generated by other methodologies would not allow merging of results from this effort with that of our previous efforts. Market research revealed Paul Ahlquist's laboratory at the University of Madison to be one of a few groups proficient and having published validated data using the Affymetrix 2.0Plus human array. Importantly, it was rare to identify any group that had capabilities to conduct this array in a high-throughput fashion and Dr. Ahlquist's group again satistified this criteria. Finally, the market research revealed that the in-house HPV array from which data were generated from previous efforts and planned for the present effort, is unique and to the University of Madison. No other groups had published data from this array and would permit consolidation of these important data with data from previous efforts. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on September 11, 2008. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation No. NCI-90211-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-90211-MM/listing.html)
- Record
- SN01930706-W 20090829/090828084442-26ba4f820a15bfb39d04694f9bd76e65 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |